Seree-aphinan, C.; Rattanakaemakorn, P.; Suchonwanit, P.; Thadanipon, K.; Ratanapokasatit, Y.; Yongpisarn, T.; Malathum, K.; Simaroj, P.; Setthaudom, C.; Lohjai, O.;
et al. Immunogenicity of Intradermal Versus Intramuscular BNT162b2 COVID-19 Booster Vaccine in Patients with Immune-Mediated Dermatologic Diseases: A Non-Inferiority Randomized Controlled Trial. Vaccines 2024, 12, 73.
https://doi.org/10.3390/vaccines12010073
AMA Style
Seree-aphinan C, Rattanakaemakorn P, Suchonwanit P, Thadanipon K, Ratanapokasatit Y, Yongpisarn T, Malathum K, Simaroj P, Setthaudom C, Lohjai O,
et al. Immunogenicity of Intradermal Versus Intramuscular BNT162b2 COVID-19 Booster Vaccine in Patients with Immune-Mediated Dermatologic Diseases: A Non-Inferiority Randomized Controlled Trial. Vaccines. 2024; 12(1):73.
https://doi.org/10.3390/vaccines12010073
Chicago/Turabian Style
Seree-aphinan, Chutima, Ploysyne Rattanakaemakorn, Poonkiat Suchonwanit, Kunlawat Thadanipon, Yanisa Ratanapokasatit, Tanat Yongpisarn, Kumthorn Malathum, Pornchai Simaroj, Chavachol Setthaudom, Onchuma Lohjai,
and et al. 2024. "Immunogenicity of Intradermal Versus Intramuscular BNT162b2 COVID-19 Booster Vaccine in Patients with Immune-Mediated Dermatologic Diseases: A Non-Inferiority Randomized Controlled Trial" Vaccines 12, no. 1: 73.
https://doi.org/10.3390/vaccines12010073
APA Style
Seree-aphinan, C., Rattanakaemakorn, P., Suchonwanit, P., Thadanipon, K., Ratanapokasatit, Y., Yongpisarn, T., Malathum, K., Simaroj, P., Setthaudom, C., Lohjai, O., Tanrattanakorn, S., & Chanprapaph, K., on behalf of COVIDVAC-DERM Study Group.
(2024). Immunogenicity of Intradermal Versus Intramuscular BNT162b2 COVID-19 Booster Vaccine in Patients with Immune-Mediated Dermatologic Diseases: A Non-Inferiority Randomized Controlled Trial. Vaccines, 12(1), 73.
https://doi.org/10.3390/vaccines12010073
